TTrialPathMatch Me to Trials
← Back to trials
RecruitingKidney Transplant Recipients

The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients

Eligible age

18+ yrs

Accepts

All genders

Locations

0 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The study aims to determine the short-term efficacy, mechanisms and safety of 12 weeks of dapagliflozin and semaglutide combination therapy in 20 KTR, with and without T2D.

Sponsor: University Health Network, Toronto

You may qualify if…

  • ✓ Signed and dated written informed consent.
  • ✓ Patients aged ≥18 years with KTR
  • ✓ \>3 months post kidney transplantation
  • ✓ Estimated glomerular filtration rate \[eGFR\] ≥20 ml/min/1.73m2
  • ✓ BP \<160/100 and \>90/60 at screening
  • ✓ Body-mass index \[BMI\] between 18.5-40kg/m2
  • ✓ In patients with T2D or PTDM, HbA1c \<12.0%;

You may not qualify if…

  • ✕ Type 1 diabetes.
  • ✕ History of multi-organ transplant
  • ✕ Acute coronary syndrome, transient ischemic attack or stroke within 30 days prior to screening
  • ✕ Impending need for kidney biopsy or rapid decline in eGFR within 30 days prior to screening
  • ✕ Actively treated BK, CMV or EBV infection
  • ✕ Recurrent pyelonephritis or need for indwelling or self-catheterization
  • ✕ Prior amputation or ischemic rest pain
  • ✕ Women who are pregnant, nursing, or who plan to become pregnant whilst in the trial.

Source: ClinicalTrials.gov · NCT05938712 · last updated 2026-05-01